Keros Therapeutics (KROS) Stock Statistics & Valuation Metrics

Keros Therapeutics has a market cap or net worth of $584.46M. The enterprise value is -$284.12M.

Keros Therapeutics has 40,615,414 shares outstanding. The number of shares has decreased by -2.65% in one year.

Keros Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.77%.

The current PE Ratio of Keros Therapeutics is ―. Keros Therapeutics’s PEG ratio is ―.

In the last 12 months, Keros Therapeutics had revenue of 3.55M and earned -187.35M in profits. Earnings per share was -5.00.

In the last 12 months, operating cash flow was 44.86M and capital expenditures -1.55M, giving a free cash flow of 43.31M billion.

Keros Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Keros Therapeutics upcoming earnings date is Oct 30, 2025, Before Open (Confirmed).

Keros Therapeutics as a current ratio of 21.45, with Debt / Equity ratio of 2.53%

In the past 12 months, Keros Therapeutics has paid 300.00K in taxes.

Keros Therapeutics EV to EBITDA ratio is -0.28, with an EV/FCF ratio of -0.32.

Keros Therapeutics has $720.54M in cash and marketable securities with $18.41M in debt, giving a net cash position of -$702.13M billion.

Gross margin is 99.70%, with operating margin of -5938.96%, and net profit margin of -5277.55%.

The average price target for Keros Therapeutics is $24.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy